Eli Lilly’s Omvoh gains FDA approval for treating Crohn’s disease
HQ Team The US Food and Drug Administration (FDA) has approved Eli Lilly’s Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active
HQ Team The US Food and Drug Administration (FDA) has approved Eli Lilly’s Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active
Obesity, as defined by the standard body mass index, is erroneous, and the condition should be split into two — pre-clinical and clinical,
At least eight people have died in Tanzania of suspected Marburg Virus Disease (MVD) and the regional risk is “high,” according to a
Tata Group, a $165 billion Indian conglomerate, is set to build a medical school in the southern technology hub of Bengaluru by partnering
Daiichi Sankyo will buy outright a cancer antibody it had licensed from Glycotope GmbH earlier for $132.5 million, according to a statement from
Eli Lilly and Company will acquire Scorpion Therapeutics’ investigational cancer drug, currently being evaluated in first- mid-stage trials to treat breast and solid
Johnson & Johnson will acquire Intra-Cellular Therapies Inc., a biopharmaceutical company developing drugs for central nervous system disorders, for $14.6 billion, according to
Bharti Jayshankar January 11, 2024: Excessive screen time of children is a growing concern as many studies have correlated cognitive and language skills
Bharti Jayshankar January 11, 2024: In a breakthrough for bladder cancer treatment, Pfizer’s experimental anti-PD-1 therapy demonstrated superior efficacy compared to the current
Biogen Inc., plans to buy all outstanding shares totalling 61.17 million of Sage Therapeutics Inc., for $7.22 a share, representing a premium of